Clinical Report: FDA expands tirzepatide indication to cardiovascular risk reduction
Overview
The FDA has approved tirzepatide for reducing the risk of major cardiovascular events in adults with type 2 diabetes at high risk. This decision is based on the SURPASS-CVOT trial, which included 13,299 participants and demonstrated noninferiority to dulaglutide in cardiovascular outcomes over a median follow-up of approximately 4 years.
Background
Cardiovascular disease is a significant concern for patients with type 2 diabetes, necessitating effective interventions to mitigate risk. Tirzepatide, a dual agonist, is approved as an adjunct to diet and exercise to improve glycemic control in patients aged 10 years and older with type 2 diabetes.
Data Highlights
Outcome
Tirzepatide
Dulaglutide
Cardiovascular death, myocardial infarction, or stroke
12.2%
13.1%
Key Findings
The FDA approved tirzepatide for cardiovascular risk reduction in type 2 diabetes.
Tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events over a median follow-up of approximately 4 years.
Common adverse events included gastrointestinal issues, primarily during dose escalation.
Warnings for tirzepatide include potential thyroid tumors and serious adverse effects such as pancreatitis and hypoglycemia.
Clinical Implications
Ongoing monitoring for gastrointestinal side effects and other serious adverse effects is essential during treatment.
Conclusion
The expanded indication for tirzepatide reflects its role in addressing cardiovascular risk in patients with type 2 diabetes.
Manufacturers would be required to notify the FDA of GRAS determinations under a proposed rule, while HHS and USDA also submitted the first proposed federal definition of ultra-processed foods for final review.
